End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings [PDF]
al., et +2 more
core +1 more source
Health-related quality of life and adherence to hydroxyurea in patients with sickle cell anemia in Saudi Arabia. [PDF]
Abualhommos AK +5 more
europepmc +1 more source
Hydroxyurea pharmacokinetics, it is a small world after all. [PDF]
Caruso C, Appiah-Kubi A.
europepmc +1 more source
DNA polymerase kappa stabilized by Ptbp2 interacts with MRE11 and promotes genomic instability in leukemia. [PDF]
Lama S +11 more
europepmc +1 more source
Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations. [PDF]
Power-Hays A +17 more
europepmc +1 more source
One cell at a time: HbF distribution in sickle cell disease. [PDF]
Khandros E, Steinberg MH.
europepmc +1 more source
Impact of telehealth on hydroxyurea adherence and clinical outcomes in sickle cell disease management: A systematic review and meta-analysis. [PDF]
Akosah A, Gokhale P, Villa Zapata L.
europepmc +1 more source
"Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?" [PDF]
Alzahrani MF +16 more
europepmc +1 more source
Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors [PDF]
Dearborn, Joshua +8 more
core +2 more sources
Priapism as an Initial Presentation of Sickle Cell Disease: A Case Report. [PDF]
Abebe SG +4 more
europepmc +1 more source

